Harrow, Inc. announced an expansion of its VEVYE Access for All (VAFA) program to include patients currently prescribed Klarity-C Drops, a compounded cyclosporine 0.1% product from Harrow's ImprimisRx subsidiary. This initiative, part of 'Project Beagle,' aims to transition approximately 25,000 Klarity-C patients to VEVYE.
Under the expanded program, these patients will be able to convert their Klarity-C prescriptions to VEVYE (cyclosporine ophthalmic solution) 0.1%, an FDA-approved treatment for dry eye disease, for $59 per bottle, including refills. This move is expected to more than double the profit per prescription, even at VEVYE's $59 cash pay price.
Klarity-C prescribers now have access to a prescription authorization platform to facilitate the transfer of prescriptions to PhilRx, Harrow's specialty pharmacy partner. This strategic transition is designed to accelerate VEVYE's market share capture and bolster prescriber confidence by ensuring affordable access to an FDA-approved treatment.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.